Showing results (121-130 of 156) with videos related to
Sort By:
Pageof 16
Leukemia|June 24, 2020
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND studyAndreas Hochhaus, Carlo Gambacorti-Passerini, Camille Abboud, et al.Blood|September 9, 2011
Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher diseaseAri Zimran, Einat Brill-Almon, Raul Chertkoff, et al.The Lancet. Oncology|July 13, 2016
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trialMaría-Victoria Mateos, Miguel-Teodoro Hernández, Pilar Giraldo, et al.Haematologica|February 6, 2010
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patientsMaría Carmen Chillón, Carlos Santamaría, Ramón García-Sanz, et al.Journal of Inherited Metabolic Disease|March 6, 2019
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trialRaphael Schiffmann, Ozlem Goker-Alpan, Myrl Holida, et al.Cancer Medicine|March 11, 2015
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 monthsLuis-Felipe Casado, José-Valentín García-Gutiérrez, Isabel Massagué, et al.The New England Journal of Medicine|August 2, 2013
Lenalidomide plus dexamethasone for high-risk smoldering multiple myelomaMaría-Victoria Mateos, Miguel-Teodoro Hernández, Pilar Giraldo, et al.British Journal of Haematology|February 5, 2020
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet countsHaifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, et al.Journal of Cancer Research and Clinical Oncology|October 25, 2017
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phaseJuan Luis Steegmann, Dolors Colomer, Maria-Teresa Gómez-Casares, et al.Blood|August 18, 2005
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMAJoan Bladé, Laura Rosiñol, Ana Sureda, et al.Pageof 16